End-Stage Renal Disease due to Polyomavirus in a Cardiac Transplant Patient

Prevention and communication of viral infections in surgical procedure recipients involves chemical reaction of immunosuppressive therapy and use of antiviral drug therapy.
There are, however, no FDA-approved antiviral treatments for PVAN.
Handling of polyomavirus contagion of the kidney is dependent on change of immunosuppressive therapy, but, as in the tense case, dose titrations should be strictly regulated by the risk of state of affairs.
There are no value protocols for chemical reaction immunosuppression, but the most common approaches involve the birth prevention of mycophenolate mofetil or azathioprine and the concomitant diminution of calcineurin inhibitor dose.
In patients at high risk of state of affairs, and in those who have not responded sufficiently to immunomodulation, one or both of the antiviral agents cidofovir and leflunomide might be used as adjunctive ‘rescue’ therapy.
This is a part of article End-Stage Renal Disease due to Polyomavirus in a Cardiac Transplant Patient Taken from "Arava Information" Information Blog